All In Biotech

Drug Trial Radar · NCT06223919

Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia

Randomized Trial to Evaluate the Efficacy/Effectiveness, Safety, and Immunogenicity of Replicative Live Attenuated Vaccinia Virus Vaccine LC16m8 for Prevention Against Mpox in High-risk Populations During Vaccination Deployment in Colombia

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 8,686 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

8,686

Planned (sponsor's estimate)

Start

Dec 16, 2023

Primary completion

Aug 20, 2024

Study completion Dec 2025

Sponsor

Lead sponsor
Universidad Nacional de ColombiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministerio de Salud y Protección Social de Colombia; Ministry of Health, Labour and Welfare, Japan; Japan Agency for Medical Research and Development; National Center for Global Health and Medicine, Japan; National Institute of Infectious Disease, Japan; Instituto Nacional de Salud
First posted
Jan 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Background: Mpox is a zoonotic disease caused by the mpox virus (MPXV). It has been endemic in West and Central African countries. However, the soaring number of those has been reported in non-endemic countries since May 2022, making World Health Organization (WHO) declare a global mpox Public Health Emergency of International Concern in July 2022. Those with mpox are primarily young men (96%, and median age of 34 \[interquartile range (IQR):29-41 years\]), and 84% are self-identified homosexual, bisexual, and men who have sex with men (MSM) . Furthermore, about half of these mpox cases with known human immunodeficiency virus 1(HIV-1, hereafter shown as HIV). WHO recommended prioritizing vaccinating those populations as high-risk populations, including those with HIV, since they will be severely ill if infected mpox virus (MPXV). The smallpox vaccine is expected to offer cross-immunity against MPXV. Under these circumstances, WHO included LC16m8 in the recommended vaccine lists for mpox as the product is expected to have cross-efficacy and immunogenicity against MPXV. Additionally, the safety profile was demonstrated in both adults and children, including infants who have low immuno-functions. Given that Colombia has the fifth highest mpox prevalence worldwide, WHO encouraged the authorities to implement vaccine programs while evaluating the safety and efficacy of LC16m8 as collaborative research. Following WHO initiative, this study is being conducted with the collaboration of various experts from Colombia and Japan on a large scale, with vaccine contributions and funding from Japan and Colombia However, the current infection situation differs from six months ago, and there have been few recent cases of MPXV infection in the country. Primary objective: To determine the efficacy of the replicating attenuated live vaccinia virus vaccine LC16m8 against laboratory-confirmed mpox and safety in a Colombian population with a high risk of being infected with MPXV(See the Inclusion Criteria), by comparing the immediate vaccination group and the delayed vaccination groups to assess safety and tolerability until 180 days after vaccination. Study design: An open randomized deployment study (1:1 Immediate and Delayed vaccination group). Study population: People at high risk of serious illness if infected with MPXV and those who engage in risk behaviors for acquiring MPXV infection.

Conditions

  • Monkeypox

Interventions

  • LC16m8Biological

    LC16m8 should be stored at temperatures between -35°C and -20°C. The product should not be stored at temperatures below -35°C, because deterioration or damage of the rubber stopper could occur. The virus in this product is sensitive to sunlight and is quickly inactivated, so care should be taken to avoid exposure to light, both before or after reconstitution. Carefully examine the content at the time of reconstitution. Do not use if precipitation, contamination of foreign substances, or other abnormalities are observed. This product should be dissolving the drug immediately before inoculation. Once dissolved, it should be used immediately. Since this product does not contain thimerosal, once the stopper is removed, any solution remained in the vial must be disposed of. Do not restore or reuse the remaining solution. Shelf Life: 10 years from the date of passing the national test for lot-release Bottle containing about 250 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rate of mpox infection between the immediate versus delayed vaccination groups from day 15 to day 56 post-vaccination of the immediate group.Time frame: For immediate vaccination group: from days 15th to 56th post vaccination. For delayed vaccination group: from enrollment to the day of vaccination (42 days later)
  2. Incidence of adverse events between the vaccination groupsTime frame: up to 6 months post vaccination
  3. Incidence rate of mpox infection between the vaccinated cohort versus the unvaccinated cohortTime frame: 6 months post vaccination

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Clinica Universitaria Colombia - Centro Medico Teusaquillo

    Bogotá, Bogota D.C., Colombia

  • Hospital Universitario San Ignacio

    Bogotá, Bogota D.C., Colombia

  • Infecto Clinicos

    Bogotá, Bogota D.C., Colombia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.